Alterity Therapeutics Limited (ATHE)
NASDAQ: ATHE · Real-Time Price · USD
3.933
+0.013 (0.34%)
At close: Jun 27, 2025, 4:00 PM
3.990
+0.057 (1.44%)
After-hours: Jun 27, 2025, 4:04 PM EDT
Alterity Therapeutics Revenue
Alterity Therapeutics had revenue of 1.61M AUD in the half year ending December 31, 2024, a decrease of -32.69%. This brings the company's revenue in the last twelve months to 3.72M, up 8.55% year-over-year. In the fiscal year ending June 30, 2024, Alterity Therapeutics had annual revenue of 4.02M with 2.63% growth.
Revenue (ttm)
3.72M AUD
Revenue Growth
+8.55%
P/S Ratio
25.92
Revenue / Employee
372,449 AUD
Employees
10
Market Cap
59.74M USD
Revenue Chart
* This company reports financials in AUD.
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
ATHE News
- 4 days ago - Alterity Therapeutics to Provide Corporate Update in Fireside Chat - GlobeNewsWire
- 6 weeks ago - Alterity Therapeutics Prominently Featured at the International MSA Congress - GlobeNewsWire
- 7 weeks ago - Alterity Therapeutics Announces Multiple Oral and Poster Presentations to be Featured at the International MSA Congress - GlobeNewsWire
- 7 weeks ago - Alterity Therapeutics Granted U.S. FDA Fast Track Designation for ATH434 to Treat Multiple System Atrophy - GlobeNewsWire
- 2 months ago - Appendix 4C – Q3 FY25 Quarterly Cash Flow Report - GlobeNewsWire
- 2 months ago - Alterity Therapeutics Presents ATH434-201 Phase 2 Clinical Trial Results at European MSA Symposium - GlobeNewsWire
- 2 months ago - Alterity Therapeutics Presents Encouraging New Data from its ATH434 Phase 2 Trial in Multiple System Atrophy at the American Academy of Neurology Annual Meeting - GlobeNewsWire
- 3 months ago - Alterity Therapeutics Completes Last Patient Visit in ATH434-202 Open-Label Phase 2 Trial in Multiple System Atrophy - GlobeNewsWire